Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

ABSTRACT:

Background

In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk.

Methods

In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up.

Results

O

SUBMITTER: Haynes BF 

PROVIDER: S-EPMC3371689 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature